发布求助
文献互助 智能选刊 最新文献

Actualites Pharmaceutiques最新文献

筛选
英文 中文
La sclérose en plaques, une maladie auto-immune chronique
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.007
Damien Malbos (Docteur en pharmacie) , Laurent Magy (Professeur des universités)
{"title":"La sclérose en plaques, une maladie auto-immune chronique","authors":"Damien Malbos (Docteur en pharmacie) ,&nbsp;Laurent Magy (Professeur des universités)","doi":"10.1016/j.actpha.2025.01.007","DOIUrl":"10.1016/j.actpha.2025.01.007","url":null,"abstract":"<div><div>La sclérose en plaques est une pathologie neurologique chronique évolutive dont le pharmacien doit connaître les différentes formes cliniques afin d’être à même de répondre aux questions des patients qui viennent à l’officine chercher leurs médicaments ou des conseils. Il est important de définir le rôle que l’équipe officinale peut jouer lors des différentes phases de la maladie.</div></div><div><div>Multiple sclerosis is a chronic, progressive neurological disease, and pharmacists need to be familiar with its various clinical forms in order to be able to answer patients’ questions when they come to the pharmacy for medication or advice. It is important to define the role that the pharmacy team can play during the different phases of the disease.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 18-22"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historique de la rémunération sur objectifs de santé publique
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.014
Jean-Michel Mrozovski (Président honoraire de la Coopération pour la valorisation de l’acte officinal)
{"title":"Historique de la rémunération sur objectifs de santé publique","authors":"Jean-Michel Mrozovski (Président honoraire de la Coopération pour la valorisation de l’acte officinal)","doi":"10.1016/j.actpha.2025.01.014","DOIUrl":"10.1016/j.actpha.2025.01.014","url":null,"abstract":"<div><div>Ce que nous continuons d’appeler les nouvelles missions a été mis en œuvre dès 2013. Aujourd’hui, le pharmacien peut pratiquer cinq entretiens d’accompagnement, un bilan partagé de médication, la vaccination, le test rapide d’orientation diagnostique de l’angine et ce, dans le cadre de la rémunération sur objectifs de santé publique.</div></div><div><div>What we continue to call the new missions were implemented back in 2013. Today, pharmacists can carry out five support interviews, a shared medication assessment, vaccinations and rapid diagnostic tests for angina, all within the framework of remuneration based on public health objectives.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 51-55"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Les médicaments de la sclérose en plaques
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.008
Pascal Coudert (Professeur des universités)
{"title":"Les médicaments de la sclérose en plaques","authors":"Pascal Coudert (Professeur des universités)","doi":"10.1016/j.actpha.2025.01.008","DOIUrl":"10.1016/j.actpha.2025.01.008","url":null,"abstract":"<div><div>Si les thérapeutiques actuelles de la sclérose en plaques ne sont pas curatives, elles permettent de réduire, d’une part, l’intensité et la fréquence des poussées et, d’autre part, la progression du handicap. Les traitements de fond de la maladie font appel à la corticothérapie pour limiter les poussées, mais aussi à des immunomodulateurs et des immunosuppresseurs dont la plupart agissent par inhibition des lymphocytes.</div></div><div><div>Although current therapies for multiple sclerosis are not curative, they can reduce the intensity and frequency of relapses, as well as the progression of disability. Disease-modifying therapies include corticosteroids to limit relapses, as well as immunomodulators and immunosuppressants, most of which act by inhibiting lymphocytes.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 23-28"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
À l’officine, une implication indispensable dans le parcours de soins du malade atteint de sclérose en plaques
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.006
Jacques Buxeraud (Professeur des universités) , Laurent Magy (Professeur des universités)
{"title":"À l’officine, une implication indispensable dans le parcours de soins du malade atteint de sclérose en plaques","authors":"Jacques Buxeraud (Professeur des universités) ,&nbsp;Laurent Magy (Professeur des universités)","doi":"10.1016/j.actpha.2025.01.006","DOIUrl":"10.1016/j.actpha.2025.01.006","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Page 17"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Partages d’expériences ville-hôpital pour sécuriser le parcours de soins des patients sous anticancéreux oraux
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.015
Robin Louche (Docteur junior) , Cyril Magnan (Pharmacien)
{"title":"Partages d’expériences ville-hôpital pour sécuriser le parcours de soins des patients sous anticancéreux oraux","authors":"Robin Louche (Docteur junior) ,&nbsp;Cyril Magnan (Pharmacien)","doi":"10.1016/j.actpha.2025.01.015","DOIUrl":"10.1016/j.actpha.2025.01.015","url":null,"abstract":"<div><div>La disponibilité des anticancéreux oraux a modifié la prise en charge en oncologie, rendant cruciale la coordination entre hôpital et ville pour assurer la sécurité des soins. Un appel à candidature, lancé en 2024, proposait des partages d’expériences entre professionnels pour optimiser la gestion des risques et la continuité des parcours patients. Le projet visait à améliorer la prévention des risques liés aux traitements, un financement étant prévu pour encourager ces collaborations.</div></div><div><div>The availability of oral anti-cancer drugs has changed the way oncology is managed, making coordination between hospital and community care crucial to ensuring safe care. A call for applications launched in 2024 proposed the sharing of experience between professionals to optimize risk management and continuity of patient pathways. The project was aimed at improving the prevention of treatment-related risks, with funding provided to encourage such collaboration.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 56-57"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Échanges autour des soins oncologiques
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.012
Jérôme Sicard (Docteur en pharmacie)
{"title":"Échanges autour des soins oncologiques","authors":"Jérôme Sicard (Docteur en pharmacie)","doi":"10.1016/j.actpha.2025.01.012","DOIUrl":"10.1016/j.actpha.2025.01.012","url":null,"abstract":"<div><div>Le congrès de l’European Society of Medical Oncology 2024 a été l’occasion d’aborder un certain nombre de problématiques liées au cancer. Il a notamment été question de l’après-cancer et de la peur de la récurrence, des effets indésirables des anticorps drogue-conjugués en cancérologie, du rôle du microbiome en tant que facteur d’amélioration de l’efficacité de certains traitements comme l’immunothérapie et de la gestion des symptômes de la ménopause.</div></div><div><div>The European Society of Medical Oncology 2024 congress addressed a number of cancer-related issues. These included post-cancer and the fear of recurrence, the adverse effects of drug-conjugated antibodies in oncology, the role of the microbiome as a factor in improving the efficacy of certain treatments such as immunotherapy, and the management of menopausal symptoms.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 43-46"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
produits
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.02.021
{"title":"produits","authors":"","doi":"10.1016/j.actpha.2025.02.021","DOIUrl":"10.1016/j.actpha.2025.02.021","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 7-8"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Médicaments dopaminergiques et neuroleptiques antipsychotiques
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.01.005
Arthur Piraux (Docteur en pharmacie, maître de conférences en pratiques officinales)
{"title":"Médicaments dopaminergiques et neuroleptiques antipsychotiques","authors":"Arthur Piraux (Docteur en pharmacie, maître de conférences en pratiques officinales)","doi":"10.1016/j.actpha.2025.01.005","DOIUrl":"10.1016/j.actpha.2025.01.005","url":null,"abstract":"<div><div>La supplémentation en dopamine est le traitement de référence de la maladie de Parkinson. L’objectif est d’apporter la dose minimale efficace pour soulager la symptomatologie le plus longtemps possible. Les neuroleptiques antipsychotiques, à l’instar de l’halopéridol, induisent quant à eux un antagonisme d’action au niveau des récepteurs dopaminergiques D2. Leur association est donc déconseillée chez les patients parkinsoniens.</div></div><div><div>Dopamine supplementation is the standard treatment for Parkinson’s disease. The aim is to provide the minimum effective dose to relieve symptoms for as long as possible. Antipsychotic neuroleptics, such as haloperidol, antagonize the action of dopamine D2 receptors. Their combination is therefore not recommended for Parkinson’s patients.</div></div>","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 14-15"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
profession
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.02.019
{"title":"profession","authors":"","doi":"10.1016/j.actpha.2025.02.019","DOIUrl":"10.1016/j.actpha.2025.02.019","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Pages 4-5"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
livres
IF 0.1
Actualites Pharmaceutiques Pub Date : 2025-03-01 DOI: 10.1016/j.actpha.2025.02.020
{"title":"livres","authors":"","doi":"10.1016/j.actpha.2025.02.020","DOIUrl":"10.1016/j.actpha.2025.02.020","url":null,"abstract":"","PeriodicalId":41434,"journal":{"name":"Actualites Pharmaceutiques","volume":"64 644","pages":"Page 6"},"PeriodicalIF":0.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143548095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信